drug · small molecule
envudeucitinib
Phase 3updated 5mo agoby $ALMS ALUMIS INC.🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.
all catalysts(0)
nothing on the calendar yet
Trials studying envudeucitinib
- phase3A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
- phase3A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
- phase2Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
- phase3Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
- phase2Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
News(5)
- This week in charts: China deals, stock flatlines and Lilly’s M&A spreeDeals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.biopharma_dive · 1mo ago
- Alumis’ TYK2 drug fails in key lupus studyThough Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.biopharma_dive · 1mo ago
- Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitorA phase 2b lupus trial of Alumis’ envudeucitinib has missed its primary and secondary endpoints. But the biotech is still moving the TYK2 inhibitor into phase 3 in the autoimmune disease, pointing…fiercebiotech · 1mo ago
- Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workersHundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted i…biopharma_dive · 4mo ago
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.biopharma_dive · 5mo ago
Data sources
last refreshed 34m ago
Found something off?
comments(0)
5-min edit window · permanent after that